Travere Recognized $113.1M IPR&D Expense in Q3 for Civorebrutinib Deal

Travere Therapeutics recognized a $113.1 million in-process research and development expense in Q3 from closing its licensing and collaboration deal with Everest Medicines for civorebrutinib.